ArticleBMC public health2009
Cost-effectiveness of Rotavirus vaccination in Vietnam.
Article in BMC public health, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam
A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam
A Phase 2b Study of Rotavin-M1 Vaccine in Vietnamese Children
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses.PharmacoEconomics - open · 2021Pooled it
- Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review.Epidemiology and infection · 2015Pooled it
- Systematic review of the economic value of diarrheal vaccines.Human vaccines & immunotherapeutics · 2014Pooled it
- A systematic review of scope and quality of health economic evaluation studies in Vietnam.PloS one · 2014Pooled it
- An overview of the perspectives used in health economic evaluations.Cost effectiveness and resource allocation : C/E · 2024Review
- Article
- Rotavirus infection in children in Southeast Asia 2008-2018: disease burden, genotype distribution, seasonality, and vaccination.Journal of biomedical science · 2020Review
- Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries.Open forum infectious diseases · 2019Article
- Isolation, molecular characterization and an artificial infection model for a variant porcine epidemic diarrhea virus strain from Jiangsu Province, China.Archives of virology · 2017Article
- Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.BMC health services research · 2017Article
- Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam.BMC public health · 2016Article
- Cost Per DALY Averted in a Surgical Unit of a Private Hospital in India.World journal of surgery · 2016Article
- The cost effectiveness of rotavirus vaccination in Iran.Human vaccines & immunotherapeutics · 2016Article
- Family impact of Rotavirus Gastroenteritis in Taiwan and Vietnam: an Ethnographic Study.BMC infectious diseases · 2015Article
- Review
- Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model.The Libyan journal of medicine · 2014Article
- Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines.Human vaccines & immunotherapeutics · 2014Article
- Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa.Cost effectiveness and resource allocation : C/E · 2014Article
- A critical literature review of health economic evaluations of rotavirus vaccination.Human vaccines & immunotherapeutics · 2013Review
- Prevalence and molecular genotyping of group a rotaviruses in Iranian children.Indian journal of virology : an official organ of Indian Virological Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death among young children. New rotavirus vaccines have recently been approved. Some previous studies have provided broad qualitative insights into the health and economic consequences of introducing the vaccines into low-income countries, representing several features of rotavirus infection, such as varying degrees of severity and age-dependency of clinical manifestation, in their model-based analyses. We extend this work to reflect additional features of rotavirus (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection), and assess the influence of the features on the cost-effectiveness of rotavirus vaccination.
methodsWe developed a Markov model that reflects key features of rotavirus infection, using the most recent data available. We applied the model to the 2004 Vietnamese birth cohort and re-evaluated the cost-effectiveness (2004 US dollars per disability-adjusted life year [DALY]) of rotavirus vaccination (Rotarix) compared to no vaccination, from both societal and health care system perspectives. We conducted univariate sensitivity analyses and also performed a probabilistic sensitivity analysis, based on Monte Carlo simulations drawing parameter values from the distributions assigned to key uncertain parameters.
resultsRotavirus vaccination would not completely protect young children against rotavirus infection due to the partial nature of vaccine immunity, but would effectively reduce severe cases of rotavirus gastroenteritis (outpatient visits, hospitalizations, or deaths) by about 67% over the first 5 years of life. Under base-case assumptions (94% coverage and $5 per dose), the incremental cost per DALY averted from vaccination compared to no vaccination would be $540 from the societal perspective and $550 from the health care system perspective.
conclusionIntroducing rotavirus vaccines would be a cost-effective public health intervention in Vietnam. However, given the uncertainty about vaccine efficacy and potential changes in rotavirus epidemiology in local settings, further clinical research and re-evaluation of rotavirus vaccination programs may be necessary as new information emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.